دوره 13، شماره 6 - ( 5-1394 )                   جلد 13 شماره 6 صفحات 344-337 | برگشت به فهرست نسخه ها

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

He B, Junping C, Li H, Weihong T, Lintao X, Shikai W. Effects of human menopausal gonadotropin on zona pellucida and pregnancy outcomes of ovarian stimulation protocols. IJRM. 2015; 13 (6) :337-344
URL: http://ijrm.ssu.ac.ir/article-1-655-fa.html
اثرات گونادوتروپین منوپوزال انسانی (hMG) بر روی زونا پلوسیدا و نتایج حاملگی در پروتکل های تحریک تخمک گذاری. International Journal of Reproductive BioMedicine. 1394; 13 (6) :344-337

URL: http://ijrm.ssu.ac.ir/article-1-655-fa.html


چکیده:   (2475 مشاهده)
مقدمه: گونادوتروپین منوپوزال انسانی (hMG) نقش مهمی در بهبود روش های کمک باروری داشته است. ولی اثرات hMG روی رشد تخمک و نتایج کلینیکی هنوز محل بحث است.
هدف: هدف این مطالعه بررسی اثرات hMG بر روی زوناپلوسیدا و نتایج کلینیکی درمان تحریک تخمک گذاری بود.
مواد و روش ها: این مطالعه گذشته نگر بر روی 150 سیکل درمان پروتکل طولانی با استفاده از هورمون تحریک کننده فولیکولی نوترکیب rFSH)) با یا بدون hMG انجام شد. تعداد تخمک های به دست آمده، میزان باروری، میزان لانه گزینی، میزان حاملگی، ضخامت Birefringence و زوناپلوسیدای تخمک ها بررسی شد.
نتایج: هیچ تفاوت معنی داری در تعداد اوسیت ها (0/73±13/9 در مقابل 0/75±11/99، 0/06 = (p، میزان بلوغ(76/84% درمقابل 83/32 ، p=0/42) (84/76% در مقابل 83/32، 0/42%=p)، میزان حاملگی (37/31% در مقابل 37/66%،0/96 =p) و میزان لانه گزینی امبریو (28/97% در مقابل 23/26%،p=0/30) در گروه r-FSH+hMG با گروه r-FSH بدست نیامد. به هر حال میزان باروری (82/95% در مقابل 78/75%، p=0/02) متفاوت بود. Birefringence زوناپلوسیدا در گروه r-FSH+hMG کمتر از گروه r-FSH بود (0/50±6/70 در مقابل 0/31±7/04، 0/53=p). اندازه ضخامت زوناپلوسیدا در متافاز II در گروه r-FSH+hMG در روزهای اول (0/14±19/20 در مقابل 0/10±18/75، 0/01=p) و دوم (0/12±18/69 در مقابل 0/14±0/00،18/17=p) باروری هر دو بیشتر از گروه r-FSH بود.
نتیجه گیری: hMG به طور مثبتی دارای اثرات بهبود باروری تخمک و همچنین Birefringence و ضخامت زوناپلوسیدا می باشد.
نوع مطالعه: Original Article |

فهرست منابع
1. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011; 95: 1031-1036. [DOI:10.1016/j.fertnstert.2010.10.021]
2. Barrenetxea G, Agirregoikoa JA, Jiménez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008; 89: 546-555. [DOI:10.1016/j.fertnstert.2007.03.088]
3. Griesinger G, Shapiro DB, Kolibianakis EM, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reprod Biomed Online 2011; 23: 457-465. [DOI:10.1016/j.rbmo.2011.06.016]
4. Wong PC, Qiao J, Ho C, Ramaraju GA, Wiweko B, Takehara Y, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online 2011; 23: 81-90. [DOI:10.1016/j.rbmo.2011.03.023]
5. Berkkanoglu M, Isikoglu M, Nurse DA, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril 2007; 88: 665-669. [DOI:10.1016/j.fertnstert.2006.11.150]
6. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 2001; 75: 324-331. [DOI:10.1016/S0015-0282(00)01701-5]
7. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004; 82: 1521-1526. [DOI:10.1016/j.fertnstert.2004.06.041]
8. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012; 97: 1108-1114. [DOI:10.1016/j.fertnstert.2012.01.130]
9. Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod BioMed Online 2009; 19: 888-898. [DOI:10.1016/j.rbmo.2009.09.012]
10. Coppola F, Port ER, Barusi L, Ferrari B, Salvarani MC, Vadora E. Profound luteinizing hormone suppression induces a deleterious follicular environment during assisted reproduction technology. Fertil Steril 2003; 79: 459-460. [DOI:10.1016/S0015-0282(02)04671-X]
11. Propst AM, Hill MJ, Bates GW, Palumbo M, Van Horne AK, Retzloff MG. Low-dose human chorionic gonadotropin may improve in-vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril 2011; 96: 898-904. [DOI:10.1016/j.fertnstert.2011.06.069]
12. Sönmezer M, Duvan CI, Özmen B, Taşçi T, Ozkavukçu S, Atabekoğlu CS. Outcomes after early or midfollicular phase LH supplementation in previous inadequate responders. Reprod BioMed Online 2010; 20: 350-357. [DOI:10.1016/j.rbmo.2009.11.022]
13. Van Horne AK, Bates GW Jr, Robinson RD, Arthur NJ, Propst AM. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization. Fertil Steril 2007; 88: 1010-1013. [DOI:10.1016/j.fertnstert.2006.12.051]
14. Ferrari B, Barusi L, Coppola F. Clinical and Endocrine Effects of Ovulation Induction with FSH and hCG Supplementation in Low Responders in the Midfollicular Phase: A Pilot Study. J Reprod Med 2002; 47: 137-143.
15. Cheng JP, He B, Huang L, Tan WH, Xue LT, Wang SK, et al. Effect of Different Infertility Etiologies on Zona Pellucida, Embryo Development and Pregnancy Outcome. Reprod Contracept 2011; 31: 347-353.
16. Cheng JP, He B, Huang L, Lu F, Wang X, Wu Z, et al. Quantitative analysis of the intensity of zona pellucida birefringence of oocytes during IVF cycles. Reprod Fertil Dev 2010; 22: 1167-1174. [DOI:10.1071/RD10047]
17. Rose RD, Gilchrist RB, Kelly JM, Thompson JG, Sutton-McDowall ML. Regulation of sheep oocyte maturation using cAMP modulators. Theriogenology 2013; 79: 142-148. [DOI:10.1016/j.theriogenology.2012.09.020]
18. Tsuji T, Kiyosu C, Akiyama K, Kunieda T. CNP/NPR2 signaling maintains oocyte meiotic arrest in early antral follicles and is suppressed by EGFR-mediated signaling in preovulatory follicles. Mol Reprod Dev 2012; 366: 308-316. [DOI:10.1002/mrd.22114]
19. Baruffi RLR, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online 2007; 14: 14-25. [DOI:10.1016/S1472-6483(10)60758-4]
20. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007; 87: 542-546. [DOI:10.1016/j.fertnstert.2006.06.059]
21. Balasch J, Fabregues F. Pregnancy after administration of high dose recombinant human LH alone to support final stages of follicular maturation in a woman with long-standing hypogonadotrophic hypogonadism. Reprod BioMed Online 2003; 6: 427-431. [DOI:10.1016/S1472-6483(10)62162-1]
22. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ceiling effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314. [DOI:10.1093/humrep/deg066]
23. Fábregues F, Creus M, Pe arrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85: 925-931. [DOI:10.1016/j.fertnstert.2005.09.049]
24. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary down regulation. Clin Endocrinol 2004; 60: 637-643. [DOI:10.1111/j.1365-2265.2004.02027.x]
25. Host E, Gabrielsen A, Lindenberg S, Smidt-Jensen S. Apoptosis in human cumulus cells in relation to zona pellucida thickness variation, maturation stage, and cleavage of the corresponding oocyte after intracytoplasmic sperm injection. Fertil Steril 2002; 77: 511-515. [DOI:10.1016/S0015-0282(01)03006-0]
26. Filicori M, Cognigni GE. Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction. J Clin Endocrinol Metab 2001; 86: 1437-1441.
27. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000; 15: 1003-1008. [DOI:10.1093/humrep/15.5.1003]
28. Weghofer A, Munne S, Brannath W, Chen S, Tomkin G, Cekleniak N, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod 2008; 23: 499-503. [DOI:10.1093/humrep/dem412]
29. Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsbøll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod 2006; 21: 2593-2600. [DOI:10.1093/humrep/del221]

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به International Journal of Reproductive BioMedicine می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2022 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb